Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage

Annals of the Rheumatic Diseases

Volumn 62, Issue 2, 2003, Pages 120-126

  Meyer, O ^a   Labarre, C ^b,h   Dougados, M ^c   Goupille, Ph ^d   Cantagrel, A ^e   Dubois, A ^f   Nicaise Roland, P ^b   Sibilia, J ^g   Combe, B ^f  

^a BICHAT HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CHU Rangueil ^*  (France)

^d UNIVERSITY HOSPITAL OF TOURS   (France)

^e CHU RANGUEIL   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; KERATIN ANTIBODY; PEPTIDE ANTIBODY; PERINUCLEAR FACTOR ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE EROSION; CONFIDENCE INTERVAL; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0037310556     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.2.120     Document Type: Article

References (41)

1. Berthelot JM, Maugars Y, Castagne A, Audrain M, Prost A. Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Ann Rheum Dis 1997;56:123-5.
2. Nienhuis RLF, Mandema E. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964;23:302-5.
3. Hoet RM, van Venrooij WJ. The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen JS, Kalden JR, Maini RN, eds. Rheumatoid arthritis. Berlin, Heidelberg: Springer, 1992:299-318.
4. Cordonnier CC, Meyer O, Palazzo E, de Bandt M, Elias A, Nicaise P, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.
5. Goldbach Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis-associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
6. Aho K, Von Essen R, Kurki P, Palosuo T, Heliovaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;20:1278-81.
7. Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ. Antikeratin antibodies in rheumatoid arthritis. BMJ 1979;ii:97-9.
8. Schellekens GA, de Jong BAW, van den HOOGEN FHJ, van de Putte LBA. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J Clin Invest 1998;101:273-81.
9. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.
10. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α and β chains of fibrin. J Immunol 2001;166:4177-84.
11. Menard HA, Lapointe E, Rochdi MD, Zhou ZJ. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000;2:429-32.
12. Schellekens GA, Visser H, de Jong BAW, van den Hoogen HJ, Hazes JNW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
13. Combe B, Eliaou JF, Daurès JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995;34:529-34.
14. Van der Heijde DMFM, van Riel PLCM, van Leuween MA, van't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
15. Young A, Corbett M, Winfield J, Jagueremada D, Williams P, Papasawas G, et al. A prognostic index for erosive changes in the hands, feet and cervical spines in early rheumatoid arthritis. Br J Rheumatol 1988;27:94-101.
16. Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 1979;66:377-84.
17. Kaarela K. Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Suppl 1985;57:5-54.
18. Van Zeben D, Hazes JMW, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a follow-up study. J Rheumatol 1993;20:1288-96.
19. Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998;57:533-9.
20. Von Essen R, Kurki P, Isomaki H, Okubo S, Autiainen H, Aho K. Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol 1993;22:267-72.
21. Munos Fernandes S, Alvarez Doforno R, Gonzales Tarrio JM, Balso A, Richi P, Fontan G, et al. Antiperinuclear factor as a prognostic marker in rheumatoid arthritis. J Rheumatol 1999;26:2572-7.
22. Janssens X, Veys EM, Verbruggen G, Declercq L. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 1988;15:1346-50.
23. Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743-6.
24. Van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, Schellekens GA, Gmelig-Meyling FHJ, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
25. Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van de Putte LB. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 1987;14:893-7.
26. Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux Lombard P, et al. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1082-8.
27. Arnett, FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. Bland JM, Altman DC. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:1036-8.
29. Lassere M, Boers M, van der Heijde D, Boonen A, Edmonds J, Saudan A, et al. Smallest detectable difference in radiological progression. J Rheumatol 1999;26:731-9.
30. Meyer O, Tauxe F, Fabregas D, Gabay C, Goycochea M, Haim T, et al. Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol 1993;11:473-8.
31. Van der Heidje DM, van Riel PL, Nuver Zwart HH, Gribnau FW, van de Putte LBA. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;i:1036-8.
32. Van Zeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol 1996;23(suppl. 44):31-3.
33. Van der Heide A, Remme CA, Hofman DM, Jacobs JWG, Bijlsma JWJ. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-74.
34. Van Zeben D, Hazes JMW, Zwinderman AH, Cats A, van der Voor EAM, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow-up study. Ann Rheum Dis, 1992;51:1029-35.
35. Möttönen TT, Hannonen P, Arvilommi M, Jokinen I, Oka M. Relation between bone erosions and rheumatoid factor IgA and IgM isotypes in recent onset rheumatoid arthritis. Scand J Rheumatol Suppl 1988;75:244-9.
36. Hulsmans HMJ, Jacobs JWG, van der Hei de DMFM, van Albada-Kuipers GA, Schenk Y, Bijlsma WJ. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
37. Drossaers-Bakker KW, Amesz E, Zwinderman AH, Breedveld FC, Hazes JMW. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1465-72.
38. Kroot EJJA, de Jong BAW, van Leeuwen MA, Swinkels H, van den Hoogen FHJ, van't HOF M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
39. Paimela L, Palosuo T, Aho K, Lukka M, Kurki P, Leirasalo-Repo M, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 2001;60:32-5.
40. Forslind K, Vincent C, Serre G, Svensson B. Antifilaggrin autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2000;29:320-2.
41. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis. A multiparameter praspective study. Arthritis Rheum 2001;44:1736-43.